Journal of Neural Transmission

, Volume 117, Issue 6, pp 699–705 | Cite as

Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses

  • C. Scheller
  • G. Arendt
  • T. Nolting
  • C. Antke
  • S. Sopper
  • M. Maschke
  • M. Obermann
  • A. Angerer
  • I. W. Husstedt
  • F. Meisner
  • E. Neuen-Jacob
  • H. W. Müller
  • P. Carey
  • V. ter Meulen
  • P. Riederer
  • E. Koutsilieri
Basic Neurosciences, Genetics and Immunology - Original Article

Abstract

Central dopaminergic (DA) systems are affected during human immunodeficiency virus (HIV) infection. So far, it is believed that they degenerate with progression of HIV disease because deterioration of DA systems is evident in advanced stages of infection. In this manuscript we found that (a) DA levels are increased and DA turnover is decreased in CSF of therapy-naïve HIV patients in asymptomatic infection, (b) DA increase does not modulate the availability of DA transporters and D2-receptors, (c) DA correlates inversely with CD4+ numbers in blood. These findings show activation of central DA systems without development of adaptive responses at DA synapses in asymptomatic HIV infection. It is probable that DA deterioration in advanced stages of HIV infection may derive from increased DA availability in early infection, resulting in DA neurotoxicity. Our findings provide a clue to the synergism between DA medication or drugs of abuse and HIV infection to exacerbate and accelerate HIV neuropsychiatric disease, a central issue in the neurobiology of HIV.

Keywords

HIV Dopamine CSF Receptors Transporters Infection 

References

  1. Aksenova MV, Silvers JM, Aksenov MY, Nath A, Ray PD, Mactutus CF, Booze RM (2006) HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett 395:235–239CrossRefPubMedGoogle Scholar
  2. Ben-Shachar D, Zuk R, Glinka Y (1995) Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 64:718–723PubMedGoogle Scholar
  3. Berger JR, Nath A (1997) HIV dementia and the basal ganglia. Intervirology 40:122–131CrossRefPubMedGoogle Scholar
  4. Berger J, Kumar M, Kumar A, Fernandez J, Levin B (1994) Cerebrospinal fluid dopamine in HIV-1 infection. AIDS 8:67–71CrossRefPubMedGoogle Scholar
  5. Czub S, Koutsilieri E, Sopper S, Czub M, Stahl-Hennig C, Muller JG, Pedersen V, Gsell W, Heeney JL, Gerlach M, Gosztonyi G, Riederer P, ter Meulen V (2001) Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol (Berl) 101:85–91Google Scholar
  6. Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, Muller JG, Stahl-Hennig C, Riederer P, Ter Meulen V, Gosztonyi G (2004) Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs. Acta Neuropathol (Berl) 107:216–226CrossRefGoogle Scholar
  7. di Rocco A, Bottiglieri T, Dorfman D, Werner P, Morrison C, Simpson D (2000) Decreased homovanillic acid in cerebrospinal fluid correlates with impaired neuropsychologic function in HIV-1-infected patients. Clin Neuropharmacol 23:190–194CrossRefPubMedGoogle Scholar
  8. Gelman BB, Spencer JA, Holzer CE 3rd, Soukup VM (2006) Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 1:410–420CrossRefPubMedGoogle Scholar
  9. Hersh BP, Rajendran PR, Battinelli D (2001) Parkinsonism as the presenting manifestation of HIV infection: improvement on HAART. Neurology 56:278–279PubMedGoogle Scholar
  10. Hutson PH, Sarna GS, Kantamaneni BD, Curzon G (1984) Concurrent determination of brain dopamine and 5-hydroxytryptamine turnovers in individual freely moving rats using repeated sampling of cerebrospinal fluid. J Neurochem 43:151–159CrossRefPubMedGoogle Scholar
  11. Itoh K, Mehraein P, Weis S (2000) Neuronal damage of the substantia nigra in HIV-1 infected brains. Acta Neuropathol (Berl) 99:376–384CrossRefGoogle Scholar
  12. Jenuwein M, Scheller C, Neuen-Jacob E, Sopper S, Tatschner T, ter Meulen V, Riederer P, Koutsilieri E (2004) Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys. J Neurovirol 10:163–170CrossRefPubMedGoogle Scholar
  13. Khanlou N, Moore DJ, Chana G, Cherner M, Lazzaretto D, Dawes S, Grant I, Masliah E, Everall IP (2009) Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol 15:131–138CrossRefPubMedGoogle Scholar
  14. Koutsilieri E, Gotz ME, Sopper S, Stahl-Hennig C, Czub M, ter Meulen V, Riederer P (1997) Monoamine metabolite levels in CSF of SIV-infected rhesus monkeys (Macaca mulatta). Neuroreport 8:3833–3836CrossRefPubMedGoogle Scholar
  15. Koutsilieri E, ter-Meulen V, Riederer P (2001) Neurotransmission in HIV associated dementia: a short review. J Neural Transm 108:767–775CrossRefPubMedGoogle Scholar
  16. Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P (2002) Parkinsonism in HIV dementia. J Neural Transm 109:767–775CrossRefPubMedGoogle Scholar
  17. Kuhn DM, Francescutti-Verbeem DM, Thomas DM (2006) Dopamine quinones activate microglia and induce a neurotoxic gene expression profile: relationship to methamphetamine-induced nerve ending damage. Ann N Y Acad Sci 1074:31–41CrossRefPubMedGoogle Scholar
  18. Kumar AM, Fernandez J, Singer EJ, Commins D, Waldrop-Valverde D, Ownby RL, Kumar M (2009) Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol 1–18Google Scholar
  19. Kure K, Weidenheim KM, Lyman WD, Dickson DW (1990) Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration. Acta Neuropathol 80:393–400CrossRefPubMedGoogle Scholar
  20. Larsson M, Hagberg L, Forsman A, Norkrans G (1991) Cerebrospinal fluid catecholamine metabolites in HIV-infected patients. J Neurosci Res 28:406–409CrossRefPubMedGoogle Scholar
  21. LaVoie MJ, Hastings TG (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19:1484–1491PubMedGoogle Scholar
  22. Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, Riederer P, Meulen VT, Koutsilieri E (2008) Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 33(9):2228–2236CrossRefPubMedGoogle Scholar
  23. Obermann M, Kuper M, Kastrup O, Yaldizli O, Esser S, Thiermann J, Koutsilieri E, Arendt G, Diener HC, Maschke M (2009) Substantia nigra hyperechogenicity and CSF dopamine depletion in HIV. J Neurol 256:948–953CrossRefPubMedGoogle Scholar
  24. Rottenberg D, Sidtis J, Strother S, Schaper K, Anderson J, Nelson M, Price R (1996) Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 37:1133–1141PubMedGoogle Scholar
  25. Sardar A, Czudek C, Reynolds G (1996) Dopamine deficits in the brain: the neurochemical basis of parkinsonian symptoms in AIDS. Neuroreport 7:910–912CrossRefPubMedGoogle Scholar
  26. Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Grunblatt E, ter Meulen V, Riederer P, Koutsilieri E (2005) Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. J Neurochem 95:377–387CrossRefPubMedGoogle Scholar
  27. Theodore S, Cass WA, Nath A, Maragos WF (2007) Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr HIV Res 5:301–313CrossRefPubMedGoogle Scholar
  28. Thomas DM, Francescutti-Verbeem DM, Kuhn DM (2006) Gene expression profile of activated microglia under conditions associated with dopamine neuronal damage. FASEB J 20:515–517PubMedGoogle Scholar
  29. Wallace DR, Dodson S, Nath A, Booze RM (2006) Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse 59:51–60CrossRefPubMedGoogle Scholar
  30. Wang GJ, Chang L, Volkow ND, Telang F, Logan J, Ernst T, Fowler JS (2004) Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 127:2452–2458CrossRefPubMedGoogle Scholar
  31. Wiley C, Soontornniyomkij V, Radhakrishnan L, Masliah E, Mellors J, Hermann S, Dailey P, Achim C (1998) Distribution of brain HIV load in AIDS. Brain Pathol 8:277–284PubMedCrossRefGoogle Scholar
  32. Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani D, Dowd DR, Capitani S, Vitale M (2000) HIV-1 Tat-mediated inhibition of the tyrosine hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem 275:4159–4165CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • C. Scheller
    • 1
  • G. Arendt
    • 2
  • T. Nolting
    • 2
  • C. Antke
    • 3
  • S. Sopper
    • 4
  • M. Maschke
    • 5
  • M. Obermann
    • 5
  • A. Angerer
    • 5
  • I. W. Husstedt
    • 6
  • F. Meisner
    • 1
  • E. Neuen-Jacob
    • 7
  • H. W. Müller
    • 3
  • P. Carey
    • 8
  • V. ter Meulen
    • 1
  • P. Riederer
    • 9
  • E. Koutsilieri
    • 1
  1. 1.Institute of Virology and ImmunobiologyUniversity of WürzburgWürzburgGermany
  2. 2.Department of NeurologyUniversity Hospital of DüsseldorfDüsseldorfGermany
  3. 3.Department of Nuclear MedicineUniversity of DüsseldorfDüsseldorfGermany
  4. 4.German Primate CenterGöttingenGermany
  5. 5.Department of NeurologyUniversity Hospital of Duisburg-EssenDuisburg-EssenGermany
  6. 6.Department of NeurologyUniversity Hospital of MünsterMünsterGermany
  7. 7.Institute of NeuropathologyUniversity of DüsseldorfDüsseldorfGermany
  8. 8.Department of PsychiatryStellenbosch UniversityCape TownSouth Africa
  9. 9.Clinical Neurochemistry, National Parkinson Foundation Center of Excellence Research Laboratory, Department of Psychiatry and PsychotherapyUniversity of WürzburgWürzburgGermany

Personalised recommendations